UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q

[X]    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
       EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2003

[ ]    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
       EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ________  TO ________


                          ALTAIR NANOTECHNOLOGIES INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


        Canada                         1-12497                      None
----------------------------    ---------------------        ------------------
(State or other jurisdiction    (Commission File No.)        (IRS Employer  No.)
of incorporation)                                              Identification

                       204 Edison Way, Reno, Nevada 89502
          ------------------------------------------------------------
          (Address of principal executive offices, including zip code)

       Registrant's telephone number, including area code: (775) 858-3750
                                                           --------------


        Indicate by check mark whether the  registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days. YES [X]   NO [ ]

         Indicate by check mark whether the registrant is an  accelerated  filer
(as defined in Rule 12b-2 of the Act).  YES [ ]   NO [X]



         As of  May  12,  2003  the  registrant  had  34,808,236  Common  Shares
outstanding.




<PAGE>



                         PART I - FINANCIAL INFORMATION

Item 1. Financial Statements
<TABLE>
<CAPTION>

                  ALTAIR NANOTECHNOLOGIES INC. AND SUBSIDIARIES
                         (An Exploration Stage Company)
                           CONSOLIDATED BALANCE SHEETS
                      (Expressed in United States Dollars)
                                   (Unaudited)

                                                          March 31,      December 31,
                                                            2003            2002
                                                        ------------    ------------
                             ASSETS
Current Assets
<S>                                                     <C>             <C>
     Cash and cash equivalents                          $    296,148    $    244,681
     Accounts receivable                                         995         132,859
     Other current assets                                     24,954          22,598
                                                        ------------    ------------
         Total current assets                                322,097         400,138

Property, Plant and Equipment, net                         7,159,232       7,349,818

Patents and Related Expenditures, net                      1,124,829       1,146,249

Other Assets                                                  18,200          18,200
                                                        ------------    ------------

                          Total Assets                  $  8,624,358    $  8,914,405
                                                        ============    ============

              LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities
     Trade accounts payable                             $    539,265    $    455,246
     Accrued liabilities                                     193,487         149,257
     Note payable - current portion                        1,300,000            --
                                                        ------------    ------------
         Total current liabilities                         2,032,752         604,503
                                                        ------------    ------------

Note Payable, Long-Term Portion                            2,549,135       3,905,040
                                                        ------------    ------------

Commitments and Contingencies

Shareholders' Equity
     Common stock, no par value,  unlimited  shares
     authorized;  32,755,941 and 30,244,348  shares
     issued and  outstanding at March 31, 2003 and
     December 31, 2002                                    44,742,453      43,787,850
     Deficit accumulated during the development stage   (40,699,982)    (39,382,988)
                                                        ------------    ------------

                   Total Shareholders' Equity              4,042,471       4,404,862
                                                        ------------    ------------

           Total Liabilities and Shareholders' Equity   $  8,624,358    $  8,914,405
                                                        ============    ============
</TABLE>

                       (See Notes to Financial Statements)

                                       2
<PAGE>



<TABLE>
<CAPTION>
                  ALTAIR NANOTECHNOLOGIES INC. AND SUBSIDIARIES
                         (An Exploration Stage Company)
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                      (Expressed in United States Dollars)
                                   (Unaudited)

                                                                                   Period
                                                                               April 9, 1973
                                                                                  (date of
                                                    Three Months Ended         inception) to
                                                         March 31,               March 31,
                                              ----------------------------
                                                   2003            2002             2003
                                              ------------    ------------    ------------
<S>                                           <C>             <C>             <C>
Sales                                         $     20,277    $     48,937    $    316,588
Cost of sales                                       14,950          30,175         126,708
                                              ------------    ------------    ------------
Gross Margin                                         5,327          18,762         189,880
                                              ------------    ------------    ------------
Operating Expenses
     Mineral exploration and development            28,714         152,188       6,546,356
     Research and development                      212,793         138,609       3,928,889
     Professional services                         184,358         226,073       3,460,800
     General and administrative expenses           557,838         608,128      14,765,635
     Depreciation and amortization                 218,625         285,699       5,733,747
     Asset impairment                                 --              --         2,759,956
                                              ------------    ------------    ------------
       Total operating expenses                  1,202,328       1,410,697      37,195,383
                                              ------------    ------------    ------------
Loss from Operations                             1,197,001       1,391,935      37,005,503
                                              ------------    ------------    ------------
Other (Income) Expense:
     Interest expense                              120,173         288,298       4,655,512
     Interest income                                  (180)           (702)       (816,125)
     Loss (gain) on foreign exchange                  --              --          (557,942)
     Loss on extinguishment of debt                   --              --           914,667
     Gain on forgiveness of debt                      --              --          (795,972)
     Loss on redemption of convertible
       debentures                                     --              --           193,256
                                              ------------    ------------    ------------
       Total other expense, net                    119,993         287,596       3,593,396
                                              ------------    ------------    ------------
Net loss                                         1,316,994       1,679,531      40,598,899
Preferential Warrant Dividend                         --              --           101,083
                                              ------------    ------------    ------------
Net Loss Applicable to Shareholders           $  1,316,994    $  1,679,531    $ 40,699,982
                                              ============    ============    ============

Loss per common share - Basic and diluted     $       0.04    $       0.07    $       4.82
                                              ============    ============    ============

Weighted average shares - Basic and diluted     30,527,826      22,842,455       8,451,107
                                              ============    ============    ============
</TABLE>

                       (See Notes to Financial Statements)



                                       3
<PAGE>



<TABLE>
<CAPTION>

                  ALTAIR NANOTECHNOLOGIES INC. AND SUBSIDIARIES
                         (An Exploration Stage Company)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                      (Expressed in United States Dollars)
                                   (Unaudited)
                                     Period
                                                                                      April 9, 1973
                                                                                         (date of
                                                              Three Months Ended      inception) to
                                                                  March 31,             March 31,
                                                      ----------------------------
                                                          2003            2002            2003
                                                      ------------    ------------    ------------
<S>                                                   <C>             <C>             <C>
Cash flows from exploration activities:
     Net loss                                         $ (1,316,994)   $ (1,679,531)   $(40,598,899)
     Adjustments to reconcile net loss to net cash
       used in exploration activities:
       Depreciation and amortization                       218,625         285,699       5,733,747
       Shares issued for services                           51,150            --           354,576
       Shares issued for interest                           38,888          69,770       1,154,923
       Issuance of stock options to non-employees            7,192           2,421       3,038,333
       Issuance of stock options to employees                 --              --            78,220
       Issuance of stock warrants                           37,368          98,280         962,229
       Amortization of discount on note payable             44,095         107,590         843,784
       Amortization of debt issuance costs                    --            63,426         504,567
       Asset impairment                                       --              --         2,759,956
       Loss on extinguishment of debt                         --              --           914,667
       Loss on redemption of convertible debentures           --              --           193,256
       Gain on forgiveness of debt                            --              --          (795,972)
       Loss on disposal of fixed assets                       --              --             1,945
       Gain on foreign exchange                               --              --          (559,179)
       Deferred financing costs written off                   --              --           515,842
     Changes in assets and liabilities
       (net of effects of acquisition):
       Accounts receivable                                 131,864          (3,412)           (995)
       Other current assets                                 (2,356)            235       1,709,644
       Other assets                                           --            44,911        (170,720)
       Trade accounts payable                               84,019         153,155         424,766
       Accrued liabilities                                  44,230         565,398          38,772
       Deferred revenue                                       --           (40,972)           --
                                                      ------------    ------------    ------------

Net cash used in exploration activities                   (661,919)       (333,030)    (22,896,538)
                                                      ------------    ------------    ------------

Cash flows from investing activities:
     Asset acquisition                                        --              --        (2,422,417)
     Purchase of property and equipment                     (6,619)        (11,094)     (3,668,044)
     Purchase of patents and related expenditures             --              --        (1,882,187)
                                                      ------------    ------------    ------------
Net cash used in investing activities                       (6,619)        (11,094)     (7,972,648)
                                                      ------------    ------------    ------------
</TABLE>

(continued)


                                       4
<PAGE>

<TABLE>
<CAPTION>
                  ALTAIR NANOTECHNOLOGIES INC. AND SUBSIDIARIES
                         (An Exploration Stage Company)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                      (Expressed in United States Dollars)
                                   (Unaudited)
                                     Period
                                                                                 April 9, 1973
                                                                                   (date of
                                                       Three Months Ended        inception) to
                                                            March 31,              March 31,
                                                  ---------------------------
                                                      2003           2002            2003
                                                  ------------   ------------    ------------
<S>                                               <C>            <C>             <C>
Cash flows from financing activities:
   Issuance of common shares for cash, net of
     issuance costs                               $    595,000   $    125,000    $ 22,103,781
   Collection of stock subscription receivable            --             --           561,300
   Issuance of shares under Employee Stock
     Purchase Plan                                     125,005           --           217,188
   Issuance of convertible debenture                      --             --         5,000,000
   Proceeds from exercise of stock options                --             --         2,708,491
   Proceeds from exercise of warrants                     --             --         4,917,805
   Issuance of related party notes                        --             --           174,243
   Issuance of notes payable                              --             --         9,505,040
   Payment of notes payable                               --             --       (11,120,816)
   Payment of related party notes                         --          (18,757)       (174,243)
   Payment on capital lease                               --           (2,312)        (27,075)
   Purchase of call options                               --             --          (449,442)
   Redemption of convertible debentures                   --             --        (2,250,938)
                                                  ------------   ------------    ------------

Net cash provided by financing activities              720,005        103,931      31,165,334
                                                  ------------   ------------    ------------

Net increase (decrease) in cash and equivalents         51,467       (240,193)        296,148

Cash and cash equivalents, beginning of period         244,681        599,884            None
                                                  ------------   ------------    ------------

Cash and cash equivalents, end of period          $    296,148   $    359,691    $    296,148
                                                  ============   ============    ============

Supplemental disclosures:
Cash paid for interest                            $     37,189       None
                                                  ============   ============

Cash paid for income taxes                             None          None
                                                  ============   ============
</TABLE>

Supplemental schedule of non-cash investing and financing activities:
For the three months ended March 31, 2003:

   - We issued  250,001 common shares to Doral 18, LLC in payment of $100,000 of
principal on our note payable.

For the three months ended March 31, 2002:

   - None

(concluded)

                       (See Notes to Financial Statements)


                                       5
<PAGE>




                  ALTAIR NANOTECHNOLOGIES INC. AND SUBSIDIARIES
                         (An Exploration Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)

Note 1.  Basis of Preparation of Financial Statements

        These unaudited interim financial statements of Altair  Nanotechnologies
Inc. and its subsidiaries  (collectively,  "Altair", "we" or the "Company") have
been prepared in accordance  with the rules and regulations of the United States
Securities  and  Exchange   Commission  (the   "Commission").   Such  rules  and
regulations allow the omission of certain  information and footnote  disclosures
normally included in financial statements prepared in accordance with accounting
principles  generally  accepted in the United States,  so long as the statements
are not  misleading.  In the  opinion of  Company  management,  these  financial
statements and  accompanying  notes contain all adjustments  (consisting of only
normal recurring adjustments) necessary to present fairly the financial position
and  results of  operations  for the  periods  shown.  These  interim  financial
statements should be read in conjunction with the audited  financial  statements
and notes thereto contained in our Annual Report on Form 10-K for the year ended
December 31, 2002, as filed with the Commission on March 17, 2003.

        The accompanying consolidated financial statements have been prepared on
a going concern  basis,  which  contemplates  the  realization of assets and the
satisfaction  of liabilities  in the normal course of business.  As shown in the
consolidated financial statements,  we incurred net losses of $1,316,994 for the
quarter  ended March 31,  2003,  and since the date of inception  have  incurred
cumulative net losses of  $40,598,899.  At March 31, 2003,  current  liabilities
exceeded current assets by $1,710,655.  These factors,  among others,  may raise
substantial doubt about the Company's ability to continue as a going concern.

        The consolidated financial statements do not include certain adjustments
relating to the  recoverability  and classification of recorded asset amounts or
the amounts and  classification of liabilities that might be necessary should we
be unable to continue as a going concern. Our continuation as a going concern is
dependent  upon  our  ability  to  generate  sufficient  cash  flow to meet  our
obligations on a timely basis, to obtain additional  financing or refinancing as
may be required,  to develop  commercially  viable  products and processes,  and
ultimately  to  establish  successful  operations.  We  are in  the  process  of
developing and commercializing ceramic oxide nanoparticle products that are made
with  our  titanium  processing   technology.   The  recoverability  of  amounts
capitalized  as property and equipment and patents and related  expenditures  is
dependent  upon our  ability to  successfully  develop and  commercialize  these
products.

        At March 31, 2003,  we had cash and cash  equivalents  of $296,148,  and
during the period April 1, 2003 through May 13, 2003 we received net proceeds of
$472,103  from sales of common  shares and  warrants.  These amounts of cash are
sufficient  to fund our basic  operations  through  June 30,  2003.  In order to
conserve  cash,  we have reduced our cash  expenditures  to the extent  possible
without  significantly  affecting  our  development  efforts with respect to the
titanium processing technology. We will require additional financing during June
2003 in order to provide working capital to fund our day-to-day operations.

         Because our  projected  near-term  sales of  nanoparticle  products are
minimal,  we expect to generate such funds through additional private placements
of our common  stock and  warrants to purchase our common stock or other debt or
equity  securities.  As of May  13,  2003,  we have no  commitments  to  provide
additional  financing  or to purchase a  significant  quantity  of  nanoparticle
products.  If we are unable to obtain  financing  on a timely  basis,  we may be
forced to more significantly curtail and, at some point, discontinue operations.

        The results of  operations  for the  three-month  period ended March 31,
2003 are not  necessarily  indicative of the results to be expected for the full
year.


Note 2. Summary of Significant Accounting Policies

        Net  Loss  Per  Common  Share - Basic  net  loss  per  common  share  is
calculated by dividing net loss by the weighted  average number of common shares
outstanding  during the period.  The existence of stock options,  warrants,  and


                                       6
<PAGE>

convertible  securities  affects  the  calculation  of loss per share on a fully
diluted basis. When a net loss is reported,  the number of shares used for basic
and  diluted  net loss per share is the same since the effect of  including  the
additional common stock equivalents would be antidilutive.

        Stock-Based  Compensation  - We have  elected to follow  the  accounting
provisions of Accounting  Principles Board (APB) Opinion No. 25,  Accounting for
Stock Issued to  Employees,  and to furnish the pro forma  disclosures  required
under Statement of Financial Accounting Standards (SFAS) No. 123, Accounting for
Stock-Based  Compensation.  To  estimate  compensation  expense  that  would  be
recognized  under  SFAS 123,  we have  used the  modified  Black-Scholes  option
pricing  model.  If we had accounted for our stock options using the  accounting
method  prescribed  by SFAS  123,  our net loss and loss per  share  would be as
follows:
<TABLE>
<CAPTION>

                                                                  Three Months Ended
                                                                       March 31,
                                                               --------------------------
                                                                   2003          2002
                                                               ------------   -----------
<S>                                                            <C>            <C>
Net loss (basic and diluted) as reported                       $  1,316,994   $ 1,679,531
Deduct: Stock-based employee compensation expense
   included in reported net loss, net of related tax effects           --           --
Add: Total stock-based employee compensation expense
   determined under fair value based method for all awards,
   net of related tax effects                                          --          38,647
                                                               ------------   -----------

Pro forma net loss                                             $  1,316,994   $ 1,718,178
                                                               ============   ===========

Loss per common share (basic and diluted):
   As reported                                                 $       0.04   $      0.07
                                                               ============   ===========
   Pro forma
                                                               $       0.04   $      0.08
                                                               ============   ===========
</TABLE>


        Recent  Accounting  Pronouncements  - In June 2001, the FASB issued SFAS
No. 143,  Accounting  for Asset  Retirement  Obligations,  which  requires asset
retirement  obligations to be recognized when they are incurred and displayed as
liabilities. SFAS No. 143 is effective for the year ending December 31, 2003. We
adopted SFAS No. 143 on January 1, 2003.  The impact was not  significant on our
consolidated financial statements.

        In  December  2002,  the  FASB  issued  SFAS  No.  148,  Accounting  for
Stock-Based Compensation-Transition and Disclosure. SFAS No. 148 amends SFAS No.
123, Accounting for Stock-Based Compensation,  to provide alternative methods of
transition  to SFAS No. 123's fair value method of  accounting  for  stock-based
employee  compensation.  SFAS No. 148 also amends the  disclosure  provisions of
SFAS No. 123 and APB Opinion No. 28,  Interim  Financial  Reporting,  to require
disclosure in the summary of significant  accounting  policies of the effects of
an entity's accounting policy with respect to stock-based employee  compensation
on reported net income and  earnings  per share in annual and interim  financial
statements.  We  adopted  this  statement  effective  January  1,  2003 but have
elected,  as permitted  under SFAS No. 123, to continue to follow the accounting
provisions of Accounting  Principles Board (APB) Opinion No. 25,  Accounting for
Stock Issued to  Employees,  and to furnish the pro forma  disclosures  required
under SFAS No. 148.

                                       7
<PAGE>

Note 3.  Common Stock

                                                          Common Stock
                                                   -------------------------
                                                                    Stated
                                                      Shares        Amount
                                                   -----------   -----------
Balance, December 31, 2002                          30,244,348   $43,787,850
Shares issued for cash                               1,750,000       595,000
Stock options issued to non-employees                     --           7,192
Shares issued for services                             110,000        51,150
Stock warrants issued                                     --          37,368
Shares issued under Employee Stock Purchase Plan       304,371       125,005
Shares issued for settlement of debt                   250,001       100,000
Shares issued for interest                              97,221        38,888
                                                   -----------   -----------
Balance, March 31, 2003                             32,755,941   $44,742,453
                                                   ===========   ===========

        On August 6, 2002, we adopted an Employee  Stock  Purchase Plan ("ESPP")
which allows  employees to purchase  common shares through  payroll  deductions.
During the quarter  ended March 31, 2003, a total of 304,371  common shares were
issued under the ESPP at prices ranging from $0.37 to $0.50 per share.

        In  accordance  with the  terms of our note  payable  to Doral  18,  LLC
("Doral"),  a conversion right with respect to $280,000 of principal  accrued on
March 1, 2003.  Effective that date,  Doral had the right to convert all or some
of the accrued  principal  into the  Company's  common shares using a conversion
price equal to 70% of the  average  closing  price of our common  shares for the
five trading  days prior to March 1, 2003.  On March 5, 2003,  Doral  elected to
exercise their  conversion right with respect to $100,000 of principal and, as a
result, we issued to them 347,222 common shares. Of this amount,  250,001 common
shares with a fair value of $100,000 relate to the payment of principal  against
the note.  The  remaining  97,221  common  shares  with a fair  value of $38,888
represent  additional  shares  issued as a result of the  beneficial  conversion
feature and were recorded as additional interest expense.

         On March 31, 2003,  we issued  1,750,000  common  shares and  1,750,000
warrants in a private placement for cash proceeds of $595,000. The warrants have
an exercise price of $1.00 per share and expire in March 2008.


Note 4.  Notes Payable

        Notes payable  consisted of the following at March 31, 2003 and December
31, 2002:
                                            March 31,           December 31,
                                              2003                  2002
                                           -----------          -----------
Note payable to BHP Minerals
   International, Inc.                     $ 2,549,135          $ 2,505,040
Note payable to Doral 18, LLC                1,300,000            1,400,000
Less current portion                        (1,300,000)                --
                                           -----------          -----------
Long-term portion of notes payable         $ 2,549,135          $ 3,905,040
                                           ===========          ===========


Note 5.  Intangible Assets

        Our  intangible  assets  consist of  patents  and  related  expenditures
associated with the titanium processing technology.  In accordance with SFAS No.
142, we are  amortizing  these assets over their  useful  lives.  The  amortized
intangible asset balance as of March 31, 2003 was:

                                       8
<PAGE>
                                     Gross                            Net
                                    Carrying     Accumulated       Carrying
                                     Amount      Amortization       Amount
                                 ------------    ------------     -----------
        Patents and related
           expenditures          $  1,517,736    $  (392,907)     $ 1,124,829

        The  weighted  average  amortization  period  for  intangible  assets is
approximately 16.5 years.  Amortization expense was $21,421 for the three months
ended  March 31,  2003,  which  represented  the  amortization  relating  to the
identified  intangible assets still required to be amortized under SFAS No. 142.
For each of the next five years,  amortization  expense  relating to intangibles
will be $85,680 per year.



ITEM 2.        MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
                       AND RESULTS OF OPERATIONS

        The  following  discussion   summarizes  the  material  changes  in  our
financial  condition  between  December  31,  2002 and  March  31,  2003 and the
material  changes in our results of operations and financial  condition  between
the three-month periods ended March 31, 2002 and March 31, 2003. This discussion
should be read in  conjunction  with  Management's  Discussion  and  Analysis of
Financial  Condition and Results of Operations  included in the Company's Annual
Report on Form 10-K for the year ended December 31, 2002.

Overview

        From  inception  through  the  end  of  1993,  our  business   consisted
principally  of the  exploration  of  mineral  properties  for  acquisition  and
exploration.  During  1994,  our  focus  changed  as we  became  engaged  in the
acquisition,  development and testing of mineral processing equipment for use in
the recovery of fine, heavy mineral particles including gold,  titanium,  zircon
and environmental contaminants.

        In 1996, we acquired all patent rights to the Campbell  Centrifugal Jig,
since modified and renamed the Altair Centrifugal Jig. Since April 1996, we have
acquired mineral leaseholds on approximately 8,700 acres of land in Tennessee. A
prefeasibility  study  issued  in July 1998  confirmed  the  existence  of heavy
minerals and suggests that the property warrants further  exploration.  Based on
the results of these independent  studies, we initiated  additional  feasibility
testing,  but have since  suspended  such  testing  due to a shortage of working
capital.

        In November  1999, we acquired all patent  applications  and  technology
related to a hydrometallurgical process developed by BHP Minerals International,
Inc.  ("BHP")  primarily for the  production of titanium  dioxide  products from
titanium bearing ores or concentrates (the "titanium processing technology") and
all tangible equipment and other assets (the "titanium  processing assets") used
by BHP to develop and implement the titanium processing technology.

        The  titanium  processing  technology  has  potential  to  produce  both
titanium  pigments,  which are commercially  traded in bulk, and  nanoparticles,
which are sold on specialty product markets. The titanium processing  technology
also has a potential  pharmaceutical  application,  a new active  pharmaceutical
ingredient  that we call  RenaZorb(TM)  for the  treatment of  hyperphosphatemia
(elevated serum phosphate levels) in patients undergoing kidney dialysis. During
2002,  and through the first quarter of 2003,  our efforts were directed  toward
these three applications of the titanium processing technology.


                                       9
<PAGE>
Liquidity and Capital Resources

         We  generated  $20,277 of sales  revenues in the first three  months of
2003 but incurred a net loss of $1,316,994.  At March 31, 2003, our  accumulated
deficit  was  $40,699,982,  or an increase of  $1,316,994  over the  accumulated
deficit at December  31,  2002.  This  increase  was due to the net loss for the
period.

         Our cash and short-term investments increased from $244,681 at December
31,  2002 to  $296,148  at March 31,  2003 due  principally  to the  receipt  of
$595,000 from the sale of common  shares and warrants as well as the  collection
of accounts  receivable  that were  outstanding  at  December  31,  2002.  These
increases in cash were partially offset by normal cash operating expenditures.

         On August 6, 2002, we adopted an Employee  Stock Purchase Plan ("ESPP")
which allows  employees to purchase  common shares through  payroll  deductions.
During the three months ended March 31, 2003, a total of 304,371  common  shares
were issued under the ESPP, resulting in proceeds of $125,005.

Current and Expected  Liquidity.
--------------------------------

         At March 31, 2003,  we had cash and cash  equivalents  of $296,148,  an
amount that would be sufficient to fund our basic  operations  through April 30,
2003.  Between  April  1,  2003  and the  filing  date of this  report,  we sold
1,396,898  common  shares and 698,449  warrants to  purchase  common  shares for
proceeds  of  $472,103.  This  additional  cash will  allow us to  continue  our
operations  through June 30, 2003.  After that date, we will require  additional
financing to provide working capital to fund our day-to-day operations.  We will
also  require  additional  financing  to continue  our  development  work on the
titanium processing technology and the Tennessee mineral property.

         In light of the decreasing price of, and limited market for, our common
shares,  our ability to continue to fund our operations  primarily through sales
of  securities  is limited,  although we expect to generate  some funds  through
offerings of our common stock and  warrants to purchase  our common  stock,  and
additional exercises of outstanding  warrants,  during the remainder of 2003. We
also expect to generate limited revenues from the sales of nanoparticle products
and fees generated from development and testing  services  provided to potential
licensors of our titanium processing technology.  As of May 13, 2003, we have no
commitments  to provide  additional  financing  for periods  after May 2003,  to
purchase  titanium dioxide  nanoparticles or to license our titanium  processing
technology.

         We also  expect to  generate  revenues  through  the  licensing  of our
titanium processing technology,  specifically the pharmaceutical  application of
the technology  (i.e.  RenaZorb(TM))  and the  application of our technology for
large-scale  titanium pigment production.  With respect to large-scale  titanium
pigment production, Altair has completed initial testing for a materials company
and has  submitted  a  phase-two  proposal  for  the  economic  evaluation  of a
demonstration  titanium  dioxide  pigment  plant  that  could be  expanded  to a
full-scale  plant with  production  capabilities of between 10-20 metric tons of
titanium dioxide pigment per year. If the phase-two proposal is accepted in some
form,  Altair  would  expect  to  generate  limited  revenues  in 2003  (but not
sufficient to cover monthly operating  expenses) in exchange for the testing and
development  work  associated  with the evaluation of a  demonstration  titanium
dioxide plant. A licensing agreement associated with a full-scale plant would be
expected to generate  significant  revenues in the  long-term,  but  significant
up-front revenues from such an agreement are unlikely.

         With respect to RenaZorb(TM), testing of this product using animals was
initiated in late 2002 and completed in April 2003, with test results indicating
that  RenaZorb(TM)  has  therapeutic  potential  in  animal  testing.  We are in
discussions  with four  pharmaceutical  companies who may be interested in doing
further testing and negotiating a license agreement. Altair is uncertain what

                                       10
<PAGE>

the  terms of such  license  agreement  would  be,  but  pharmaceutical  license
agreements often involve up front or staged  payments,  in addition to royalties
once the drug is approved by the FDA and marketed. Based on our understanding of
terms of  license  agreements  under  similar  circumstances,  we  believe  that
up-front or early stage payments associated with such a license agreement may be
large enough to provide  liquidity for Altair  throughout  2003, and even permit
Altair to report one-time profitability during 2003. We can, however, provide no
assurance that we will enter into such a license  agreement or that such license
agreement would involve any significant  up-front payments.  If we are unable to
enter into a license  agreement with respect to  RenaZorb(TM) or another product
during  the  first  six  months  of 2003 (or  otherwise  consummate  one or more
significant  licensing,  sale or  equity  transactions),  we will be  forced  to
significantly  curtail our operations and expenses,  and our ability to continue
as a going concern will be uncertain.

Capital  Commitments
--------------------

         The  following  table  discloses   aggregate   information   about  our
contractual  obligations  including  notes  payable,   mineral  lease  payments,
facilities lease payments and contractual service agreements, and the periods in
which payments are due as of March 31, 2003:

<TABLE>
<CAPTION>
                                                      Less Than                               After
Contractual Obligations                   Total         1 Year      1-3 Years   4-5 Years    5 Years
--------------------------------        ----------    ----------   ----------   ----------   ----------
<S>                                     <C>           <C>          <C>          <C>          <C>
Notes Payable                           $4,300,000*   $1,300,000   $  600,000   $1,200,000   $1,200,000
Mineral Leases                           1,135,021       181,410      452,868      392,055      108,688
Contractual Service Agreements             494,122       344,122      100,000       50,000         --
                                        ----------    ----------   ----------   ----------   ----------
Total Contractual Obligations           $5,929,143    $1,825,532   $1,152,868   $1,642,055   $1,308,688
                                        ==========    ==========   ==========   ==========   ==========
</TABLE>
* Before discount of $450,865.


Critical Accounting Policies and Estimates

         Management   based  this  discussion  and  analysis  of  our  financial
condition and results of operations on our  consolidated  financial  statements.
The preparation of these financial  statements requires us to make estimates and
judgments that affect the reported amounts of assets,  liabilities,  revenue and
expenses,  and related  disclosure of contingent  assets and liabilities.  On an
on-going  basis,  we evaluate our critical  accounting  policies and  estimates,
including those related to long-lived  assets and stock-based  compensation.  We
base our estimates on  historical  experience  and on various other  assumptions
that we believe to be reasonable under the  circumstances,  the results of which
form the basis for  making  judgments  about the  carrying  values of assets and
liabilities that are not readily apparent from other sources. Actual results may
differ from these estimates under different assumptions or conditions.

         We believe the following critical  accounting  policies affect the more
significant  judgments and estimates used in the preparation of our consolidated
financial statements.  These judgments and estimates affect the reported amounts


                                       11
<PAGE>

of assets and  liabilities  and the  reported  amounts of revenues  and expenses
during the reporting  periods.  Changes to these  judgments and estimates  could
adversely affect the Company's future results of operations and cash flows.

         o    Long-lived  assets.  Our long-lived assets consist  principally of
              titanium processing assets, the intellectual property (patents and
              patent applications)  associated with it, and a building. At March
              31, 2003,  the carrying value of these assets was  $8,267,239,  or
              96% of total assets.  We evaluate the carrying value of long-lived
              assets when events or  circumstances  indicate  that an impairment
              may exist.  In our  evaluation,  we estimate the net  undiscounted
              cash flows  expected to be generated by the assets,  and recognize
              impairment  when such cash  flows  will be less than the  carrying
              values.  Events or circumstances that could indicate the existence
              of a possible  impairment include  obsolescence of the technology,
              an absence of market  demand for the  product,  and/or  continuing
              technology rights protection.

         o    Stock-Based  Compensation.  We have two stock  option  plans which
              provide for the issuance of stock options to employees and service
              providers.  Although Statement of Financial  Accounting  Standards
              ("SFAS")  No.  123,   Accounting  for  Stock  Based  Compensation,
              encourages   entities  to  adopt  a  fair-value-based   method  of
              accounting  for stock options and similar equity  instruments,  it
              also allows an entity to continue measuring  compensation cost for
              stock-based  compensation  using  the  intrinsic-value  method  of
              accounting  prescribed  by  Accounting  Principles  Board  ("APB")
              Opinion No. 25, Accounting for Stock Issued to Employees.  We have
              elected  to  follow  the  accounting  provisions  of APB 25 and to
              furnish the pro forma disclosures required under SFAS No. 123, but
              we also  issue  warrants  and  options to  non-employees  that are
              recognized  as  expense  when  issued  in   accordance   with  the
              provisions  of SFAS No. 123.  We  calculate  compensation  expense
              under SFAS No. 123 using a modified  Black-Scholes  option pricing
              model. In so doing, we estimate  certain key variables used in the
              model.  We  believe  the  estimates  we use  are  appropriate  and
              reasonable.

Results of Operations

         Our first  quarter of 2003 ended March 31, 2003.  For the first quarter
of 2003, net losses totaled  $1,316,994  ($.04 per share) compared to $1,679,531
($.07 per share) for the same period of 2002.  Principal factors contributing to
the losses during these periods were the lack of  substantial  revenue  together
with the incurrence of operating expenses.

         For the first  quarter of 2003,  we generated  revenues of $20,277.  Of
this  amount,  $1,581 came from sales of  titanium  dioxide  nanoparticles.  The
remaining  $18,696 of revenues came from fees earned under a services  agreement
entered into with a materials  company in September 2002. Under the terms of the
services agreement,  we tested the materials  company's mineral  concentrates in
the  production  of titanium  dioxide  pigments  using our  titanium  processing
technology.  The testing is complete and a proposal for further development work
has been given to the materials company for evaluation.

         We significantly reduced our expenditures for mineral exploration and
development in order to conserve cash for operating requirements and development
of the titanium  processing  technology.  Accordingly,  mineral  exploration and


                                       12
<PAGE>

development expenses decreased by $123,474 from $152,188 in the first quarter of
2002 to $28,714  in the first  quarter of 2003.  We expect our  expenditures  on
mineral exploration and development to remain low throughout 2003.

         Our research and  development  ("R&D")  efforts in the first quarter of
2003 were directed  principally to pharmaceuticals  and titanium pigment process
development.  R&D  expenses  increased  by $74,184  from  $138,609  in the first
quarter of 2002 to $212,793 in the same period of 2003,  principally as a result
of increased  staff time being  devoted to these R&D  projects  with a resulting
decrease in time spent on mineral  exploration  and development  activities.  We
expect our R&D  expenses  for the  remainder  of fiscal 2003 to remain at levels
higher than those of fiscal 2002.

         Professional services,  which consist principally of legal,  consulting
and audit expenses,  decreased by $41,715 from $226,073 during the first quarter
of 2002 to $184,358 in the first quarter of 2003.  The decrease is  attributable
to a decline in  consulting  expenses  of  $46,000  resulting  principally  from
decreases in warrants granted to outside service providers.

         General and administrative  expenses decreased by $50,290 from $608,128
in first  quarter of 2002 to $557,838 in the same period of 2003.  Sample  costs
decreased  by $22,000 as more effort was placed into  development  projects  and
less into sample preparation. In addition, rents decreased by $67,000 due to our
purchase,  in August 2002,  of the 204 Edison Way building  that was  previously
leased. Other general corporate expenses were reduced by a net amount of $5,000.
Offsetting  these  reductions was an increase in investor  relations  expense of
$44,000. In the first quarter of 2003, we paid an investor relations firm 75,000
common  shares  with a value  of  $37,500  for  assistance  with a new  investor
relations program.

         During the second quarter of 2002, we recorded an asset  impairment for
the jig assets which  reduced  their  depreciable  balance to zero. As a result,
depreciation  is no  longer  recorded  for these  assets  and  depreciation  and
amortization  expense decreased by $67,074 from $285,699 in the first quarter of
2002 to $218,625 in the first quarter of 2003.

         Interest  expense  decreased  by  $168,125  from  $288,298 in the first
quarter of 2002 to $120,173 in the first quarter of 2003. The decrease is due to
an amendment of our note payable to Doral 18, LLC in November 2002 which,  among
other things, reduced the balance from $2,000,000 to $1,400,000.  The accounting
guidance  provided by EITF 96-19,  Debtor's  Accounting  for a  Modification  or
Exchange of Debt Instruments,  required that the amended note be recorded at its
face amount  with no  discount,  whereas  the prior note had been  recorded at a
discount with subsequent  amortization of the discount to interest expense. This
elimination  of the debt  discount  expense,  together with the decrease in note
balance,  is  responsible  for the  decrease in interest  expense from the first
quarter of 2002 to the first quarter of 2003.


Forward-Looking Statements

        This   Quarterly   Report  on  Form  10-Q   (this   "Report")   contains
forward-looking  statements  within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended.  Such statements can be identified by the use of the forward-looking
words  "anticipate,"   "estimate,"  "project,"  "likely,"  "believe,"  "intend,"
"expect,"  or similar  words.  These  statements  discuss  future  expectations,
contain  projections  regarding future  developments,  operations,  or financial
conditions,  or state  other  forward-looking  information.  Statements  in this
report  regarding the ability of the Company to raise working capital  necessary
to fund our operations,  development of the titanium  processing  technology and
assets (including for  pharmaceutical  use),  development of the centrifugal jig
and the Tennessee mineral property,  and any future  acquisition  activities are


                                       13
<PAGE>

forward-looking  statements.  You should  keep in mind that all  forward-looking
statements are based on management's  existing  beliefs about present and future
events outside of management's  control and on assumptions  that may prove to be
incorrect.

        Among the key factors  that may have a direct  bearing on the  Company's
operating results are various risks and uncertainties including, but not limited
to, the following:

         o    We have not generated any substantial  operating  revenues and may
              not ever generate substantial revenues.

         o    As shown in the consolidated  financial statements for the quarter
              ended March 31, 2003, we incurred a net loss of $1,316,994 for the
              quarter ended March 31, 2003, and since the date of inception have
              incurred cumulative net losses of $40,598,899.  At March 31, 2003,
              current liabilities  exceeded current assets by $1,710,655.  These
              factors,  among  others,  may raise  substantial  doubt  about the
              Company's ability to continue as a going concern.

         o    We may not be able to  raise  sufficient  capital  to meet  future
              obligations.  As  described  in this  Report,  we  need  to  raise
              additional capital in the short-term and in the long-term in order
              to  continue  our  basic,   day-to-day   operations  and  continue
              development  of  the  titanium  processing  technology.  If we are
              unable  to  obtain  sufficient  capital,  we may be unable to meet
              future  obligations  or  adequately  exploit  existing  or  future
              opportunities, and may be forced to discontinue operations.

         o    The sale in the open  market of common  shares  issuable  upon the
              exercise of exchange rights under existing and recently terminated
              notes,  options and  warrants may place  downward  pressure on the
              market  price  of  our  common  shares.  Speculative  traders  may
              anticipate  the  exercise of exchange  rights or warrants  and, in
              anticipation  of a  decline  in the  market  price  of our  common
              shares,  engage in short  sales of our common  shares.  Such short
              sales  could  further  negatively  affect the market  price of our
              common shares.

         o    We have pledged all of the intellectual property, fixed assets and
              common  stock  of  Altair  Nanomaterials,  Inc.,  our  second-tier
              wholly-owned  subsidiary,  to secure  repayment  of a Secured Term
              Note with a face value of $1,400,000  issued on November 21, 2002.
              Altair   Nanomaterials,   Inc.  owns  and  operates  the  titanium
              processing  technology we acquired  from BHP in 1999.  The Secured
              Term  Note is also  secured  by a pledge of the  common  stock and
              leasehold assets of Mineral Recovery Systems, Inc., which owns and
              operates our leasehold  interests in the Camden,  Tennessee  area.
              The  Secured  Term  Note is due and  payable  on  March  31,  2004
              (subject to immediate call if the transaction in which the Secured
              Term Note was  issued  is not  approved  at our June  2003  annual
              meeting).  If we default on the Secured Term Note, severe remedies
              will likely be  available  to the holder of the Secured Term Note,
              including immediate seizure and disposition of all pledged assets.

         o    Our ability to remain  listed on the Nasdaq  SmallCap  Market will
              depend upon our ability to increase the market price of our common
              stock to $1.00 per share and to satisfy other listing  criteria by
              the end of a  probationary  period  which  expires  in June  2003.
              Delisting from the Nasdaq  SmallCap  Market may have a significant
              negative impact on the trading price,  volume and marketability of
              our common shares.

                                       14
<PAGE>

         o    In the short  run,  to the  extent  we  generate  any  significant
              revenue,  we expect such revenue to come through the  licensing of
              our   titanium    processing    technology,    specifically    the
              pharmaceutical  application of the technology (i.e.  RenaZorb(TM))
              and the  application of our technology  for  large-scale  titanium
              pigment production. With respect to both possible applications, we
              have conducted, and/or interested parties have conducted,  initial
              testing,  and we are in  discussions  regarding  follow up testing
              that could  reasonably  lead to a significant  license  agreement.
              However,  with respect to both possible  applications,  we have no
              formal or  informal  commitments  to license  our  technology  and
              cannot predict when, or if, any  significant  licensing  agreement
              will be  signed.  If we are  unable  to enter  into such a license
              agreement  during  the  first  six  months  of 2003 (or  otherwise
              consummate  one or more  significant  licensing,  sale  or  equity
              transactions),  we will be forced  to  significantly  curtail  our
              operations  and  expenses,  and our ability to continue as a going
              concern will be uncertain.

         o    In the  short  run,  we also plan to use the  titanium  processing
              technology  to produce TiO2  nanoparticles,  and we also intend to
              license the  technology to others.  TiO2  nanoparticles  and other
              products  we  intend  to  initially   produce  with  the  titanium
              processing  technology generally must be customized for a specific
              application working in cooperation with the end user. We are still
              testing and customizing our TiO2 nanoparticle products for various
              applications  and have no long-term  agreements  with end users to
              purchase any of our TiO2 nanoparticle  products.  In addition,  we
              have  not  yet  entered  into  any   agreements   to  license  the
              technology.  We may be  unable  to recoup  our  investment  in the
              titanium processing technology and titanium processing equipment.

         o    We have not completed  testing of, or developed a production model
              of,  any  series  of the jig.  In part  because  of our  liquidity
              shortage,  we do not expect to complete testing and development of
              the jig during the coming year and have  determined  to focus most
              of our limited resources on the titanium processing technology. We
              may never develop a production model of the jig.

         o    Our capital shortage has also forced us to discontinue development
              work  on the  Tennessee  mineral  property  and  make  only  those
              expenditures  that are  necessary  to maintain  the  property.  If
              additional  capital  becomes  available,  we intend to resume  the
              process of conducting feasibility testing of the Tennessee mineral
              property.  Because  we are at an early  stage of  testing,  we are
              unable to  provide  any  assurance  that  mining of the  Tennessee
              mineral  property is feasible.  Our test  production  at the pilot
              plant, economic analysis and additional exploration activities may
              indicate any of the following:

              o  that the  Tennessee  mineral  property  does not contain  heavy
                 minerals of a sufficient  quantity,  quality or  continuity  to
                 permit any mining;
              o  that production costs exceed anticipated revenues;
              o  that end products do not meet market  requirements  or customer
                 expectations;
              o  that there is an insufficient  market for products minable from
                 the Tennessee mineral property; or
              o  that mining the  Tennessee  mineral  property is otherwise  not
                 economically or technically feasible.


        In  addition to the  foregoing,  we  recommend  that you review the risk
factors and other cautionary statements contained in the Company's other filings
with the  Securities  and Exchange  Commission,  including the Company's  Annual
Report on Form 10-K for the year ended December 31, 2002.

                                       15
<PAGE>

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

        We do not have any derivative  instruments,  commodity  instruments,  or
other  financial  instruments  for trading or speculative  purposes,  nor are we
presently at risk for changes in foreign currency exchange rates.

Item 4.  Controls and Procedures

     (a) Under the  supervision  and with the  participation  of our management,
including our principal  executive officer and principal  financial officer,  we
conducted an evaluation of our disclosure controls and procedures,  as such term
is defined under Rule 13a-14(c) promulgated under the Securities Exchange Act of
1934, as amended (the "Exchange Act"), within 90 days of the filing date of this
report. Based on this evaluation,  our principal executive officer and principal
financial  officer  concluded  that our  disclosure  controls and procedures are
effective in alerting them on a timely basis to material information relating to
our Company (including its consolidated subsidiaries) required to be included in
our reports filed or submitted under the Exchange Act

     (b) There have been no significant  changes  (including  corrective actions
with regard to significant  deficiencies or material weaknesses) in our internal
controls or in other  factors that could  significantly  affect  these  controls
subsequent to the date of the evaluation referenced in paragraph (a) above.


                           PART II - OTHER INFORMATION


Item 2.  Changes in Securities and Use of Proceeds

         During the quarter ended March 31, 2003, we issued 75,000 common shares
to a consultant in a private placement pursuant to the terms of a contract under
which the consultant will provide consultant services to the Company and. 35,000
common  shares to a second  consultant  in a private  placement  pursuant to the
terms of a contract under which the consultant will provide advisory services to
the Company. Both such transactions were effected in reliance upon the exemption
for sales of securities not involving a public offering, as set forth in Section
4(2) of the  Securities Act based upon the  following:  (a) each  consultant had
such background,  education, and experience in financial and business matters as
to be able to evaluate the merits and risks of an investment in the  securities;
(b) there was no public  offering or general  solicitation  with  respect to the
offering, and each consultant confirmed that it was acquiring the securities for
its own account and not with an intent to distribute such  securities;  (c) each
consultant  was provided with a copy of the most recent  Annual  Reports on Form
10-K,  Quarterly  Reports  on Form 10-Q and  Current  Reports on Form 8-K of the
Company and all other  information  requested by the consultant  with respect to
the  Company;  (d)  each  consultant  acknowledged  that  all  securities  being
purchased were  "restricted  securities" for purposes of the Securities Act, and
agreed to transfer such securities only in a transaction registered with the SEC
under the Securities Act or exempt from  registration  under the Securities Act;
and (e) a legend was placed on the certificates and other documents representing
each such security  stating that it was restricted and could only be transferred
if  subsequently  registered  under  the  Securities  Act  or  transferred  in a
transaction exempt from registration under the Securities Act.

         In addition, during the quarter ended March 31, 2003, we sold 1,750,000
common  shares and  1,750,000  Series 2003B  warrants in exchange for  aggregate
consideration  of  $595,000  in a private  placement  to a single  institutional
accredited investor.  The warrants have an exercise price of $1.00 per share and
expire in March 2008. Such common shares and warrants were offered and sold in

                                       16
<PAGE>

reliance  upon the  exemption  for sales of  securities  not  involving a public
offering,  as set  forth  in  Section  4(2) of the  Securities  Act and Rule 506
promulgated under the Securities Act based upon the following:  (a) the investor
represented  and  warranted  to  the  Company  that  it  was  an   institutional
"accredited  investor," as defined in Rule 501 of Regulation D promulgated under
the  Securities  Act and had  such  background,  education,  and  experience  in
financial and business matters as to be able to evaluate the merits and risks of
an investment  in the  securities;  (b) there was no public  offering or general
solicitation  with  respect  to the  offering;  the  investor  was any  existing
shareholder  of the Company and the investor  represented  and warranted that it
was  acquiring  the  securities  for its own  account  and not with an intent to
distribute  such  securities;  (c) the investor  was  provided  with an offering
summary,  a copy of the most  recent  Annual  Reports  on Form  10-K,  Quarterly
Reports  on Form 10-Q and  Current  Reports on Form 8-K of the  Company  and all
other information requested by the investor with respect to the Company, (d) the
investor  acknowledged  that all securities  being  purchased  were  "restricted
securities"  for purposes of the  Securities  Act,  and agreed to transfer  such
securities  only in a transaction  registered  with the SEC under the Securities
Act or exempt from  registration  under the Securities Act; and (e) a legend was
placed on the certificates and other documents  representing  each such security
stating that it was restricted  and could only be  transferred  if  subsequently
registered under the Securities Act or transferred in a transaction  exempt from
registration under the Securities Act.


Item 6.  Exhibits and Reports on Form 8-K

a) See Exhibit Index attached hereto.

b) No reports on Form 8-K have been filed during the first quarter of 2003.



                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                    Altair Nanotechnologies Inc.



 May 14, 2003              By:  /s/ William P. Long
---------------------           --------------------------------------------
 Date                           William P. Long, Chief Executive Officer



May 14, 2003               By:  /s/ Edward H. Dickinson
---------------------           --------------------------------------------
Date                            Edward H. Dickinson, Chief Financial Officer



                                       17
<PAGE>
                                 CERTIFICATIONS

I, William P. Long, certify that:

         1. I have  reviewed  this  quarterly  report  on Form  10-Q  of  Altair
Nanotechnologies Inc.;

         2. Based on my knowledge,  this  quarterly  report does not contain any
untrue  statement of a material fact or omit to state a material fact  necessary
to make the  statements  made,  in light of the  circumstances  under which such
statements  were made, not misleading with respect to the period covered by this
quarterly report;

         3. Based on my knowledge, the financial statements, and other financial
information  included in this quarterly  report,  fairly present in all material
respects the financial  condition,  results of operations  and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

         4. The registrant's other certifying officers and I are responsible for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

                  a) designed such disclosure  controls and procedures to ensure
         that material  information  relating to the  registrant,  including its
         consolidated  subsidiaries,  is made known to us by others within those
         entities, particularly during the period in which this quarterly report
         is being prepared;

                  b) evaluated the effectiveness of the registrant's  disclosure
         controls and procedures as of a date within 90 days prior to the filing
         date of this quarterly report (the "Evaluation Date"); and

                  c) presented in this quarterly  report our  conclusions  about
         the  effectiveness  of the disclosure  controls and procedures based on
         our evaluation as of the Evaluation Date;

         5. The  registrant's  other  certifying  officers and I have disclosed,
based on our most recent evaluation,  to the registrant's auditors and the audit
committee  of  registrant's  board  of  directors  (or  persons  performing  the
equivalent function):

                  a) all significant  deficiencies in the design or operation of
         internal controls which could adversely affect the registrant's ability
         to  record,  process,  summarize  and  report  financial  data and have
         identified  for the  registrant's  auditors any material  weaknesses in
         internal controls; and

                  b)  any  fraud,   whether  or  not  material,   that  involves
         management  or  other  employees  who  have a  significant  role in the
         registrant's internal controls; and

         6. The registrant's  other certifying  officers and I have indicated in
this quarterly report whether or not there were significant  changes in internal
controls or in other factors that could  significantly  affect internal controls
subsequent to the date of our most recent  evaluation,  including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: May 14, 2003
                                  /s/ William P. Long
                                 -----------------------------------------------
                                  William P. Long
                                  Chief Executive Officer

                                       18
<PAGE>

I, Edward Dickinson, certify that:

         1. I have  reviewed  this  quarterly  report  on Form  10-Q  of  Altair
Nanotechnologies Inc.;

         2. Based on my knowledge,  this  quarterly  report does not contain any
untrue  statement of a material fact or omit to state a material fact  necessary
to make the  statements  made,  in light of the  circumstances  under which such
statements  were made, not misleading with respect to the period covered by this
quarterly report;

         3. Based on my knowledge, the financial statements, and other financial
information  included in this quarterly  report,  fairly present in all material
respects the financial  condition,  results of operations  and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

         4. The registrant's other certifying officers and I are responsible for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

                  a) designed such disclosure  controls and procedures to ensure
         that material  information  relating to the  registrant,  including its
         consolidated  subsidiaries,  is made known to us by others within those
         entities, particularly during the period in which this quarterly report
         is being prepared;

                  b) evaluated the effectiveness of the registrant's  disclosure
         controls and procedures as of a date within 90 days prior to the filing
         date of this quarterly report (the "Evaluation Date"); and

                  c) presented in this quarterly  report our  conclusions  about
         the  effectiveness  of the disclosure  controls and procedures based on
         our evaluation as of the Evaluation Date;

         5. The  registrant's  other  certifying  officers and I have disclosed,
based on our most recent evaluation,  to the registrant's auditors and the audit
committee  of  registrant's  board  of  directors  (or  persons  performing  the
equivalent function):

                  a) all significant  deficiencies in the design or operation of
         internal controls which could adversely affect the registrant's ability
         to  record,  process,  summarize  and  report  financial  data and have
         identified  for the  registrant's  auditors any material  weaknesses in
         internal controls; and

                  b)  any  fraud,   whether  or  not  material,   that  involves
         management  or  other  employees  who  have a  significant  role in the
         registrant's internal controls; and

         6. The registrant's  other certifying  officers and I have indicated in
this quarterly report whether or not there were significant  changes in internal
controls or in other factors that could  significantly  affect internal controls
subsequent to the date of our most recent  evaluation,  including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: May 14, 2003
                                  /s/ Edward H. Dickinson
                                  ----------------------------------------------
                                  Edward H. Dickinson
                                  Chief Financial Officer


<PAGE>

<TABLE>
<CAPTION>


                                  EXHIBIT INDEX

  Exhibit No.                          Exhibit                            Incorporated by Reference/Filed Herewith
----------------  ---------------------------------------------------    ---------------------------------------------
<S>              <C>                                                     <C>
      3.1         Articles of Continuance                                Incorporated by reference to the Current
                                                                         Report on Form 8-K filed with the SEC on
                                                                         July 18, 2002

      4.1         Bylaw No. 1                                            Incorporated by reference to the Current
                                                                         Report on Form 8-K filed with the SEC on
                                                                         July 18, 2002

      4.2         Form of 2003B Warrant                                  Filed herewith

     10.1         Amendment No. 1 to the Registrant 2002 Wage            Incorporated by reference to the
                  Stock  Purchase Plan                                   Registration Statement on Form S-8, file
                                                                         no. 333-104435, filed with the SEC on April 10,
                                                                         2003

     99.1         Certification of Chief Executive Officer               Filed herewith

     99.2         Certification of Chief Financial Officer               Filed herewith

</TABLE>



                                       19